ImmuDyne Signs Exclusive License Agreement for Proprietary Dermatologist Backed Hair Loss Product
September 09 2016 - 8:00AM
ImmuDyne (OTCQB:IMMD), a leader in the development and marketing of
OTC health and wellness products addressing large unmet needs,
today announced the signing of a definitive agreement with Pilaris
Laboratories, LLC (“Pilaris”), for a sole and exclusive worldwide
license to commercialize the patented PilarisMax line of hair loss
products.
As ImmuDyne previously stated, Pilaris was founded by two
prominent dermatologists, Steven D. Shapiro M.D. and Michael T.
Borenstein M.D. Ph.D. after 5 years of clinical research on topical
dihydrotestosterone (DHT) inhibitors. Dr. Shapiro has over 20 years
of clinical experience with treating hair loss and hair transplant
procedures. Dr. Borenstein holds a Ph.D. in Pharmacology and has a
background in scientific research in addition to over 12 years of
clinical dermatology practice.
“We are very pleased to finalize this licensing opportunity with
Dr. Shapiro and Dr. Borenstein and look forward to an expected
successful product launch in late 2016,” stated Mark McLaughlin,
President & CEO of ImmuDyne. “After thorough due
diligence and a global competitive analysis, we believe that the
Pilaris products have a better scientific foundation than any
similar products currently on the market.”
“Our products have been successfully sold over the past few
years via our dermatology practice, website, and friends and
family,” stated Steven Shapiro M.D. “We ’re thrilled to be
passing the baton to ImmuDyne’s team of experienced marketing
professionals to build what we believe will be a leading brand in
the men’s and women’s hair loss category.”
Branding, positioning and business development efforts for the
Pilaris product line are already underway. A beta launch is
currently planned for November 1, 2016.
About lmmuDyne
lmmuDyne, Inc. (the "Company") is a health and wellness company
which develops, manufactures, markets, and sells innovative
lifestyle products. The Company's lead products contain its
proprietary yeast beta glucans that have been shown through testing
and analysis to support the immune system. The Company's products
include once a day oral intake capsules as well as topical serums
and creams for skin application. lmmuDyne also has developed a
proprietary natural delivery technology for potential new market
opportunities. All of lmmuDyne's intellectual property is protected
by patents and/or trade secrets. Additional information can be
found on the web at www.immudyne.com.
Forward-Looking Statements
Cautionary language regarding Forward-Looking Statements Safe
Harbor Act Disclaimer: Forward looking statements in this release
are made pursuant to the Safe Harbor Provisions of the Private
Securities Litigation Reform Act of 1995. Certain statements in
this press release, including projections with respect to
lmmuDyne's results of operations, may contain words such as
"anticipates," "believes," "could," "estimates," "expects,"
"intends," "may," "projects," "plans," "targets" and other
similar language and are considered forward-looking statements.
These statements are based on management's current expectations,
estimates, and forecasts. These forward-looking statements are
subject to important assumptions, risks and uncertainties, which
are difficult to predict and therefore the actual results may be
materially different from those discussed.
Contact:
lmmuDyne, Inc.
Mark McLaughlin: +1-914-714-8901